An article by Lisa Jarvis, in the
October 1 issue of C&E News, reports that the French pharmaceutical
company, Sanofi, will cut 900 jobs in France in an effort to improve R&D
efficiency.
Congratulations to Sanofi in recognizing that R&D is a part of business success. If there is no progress with the development of new products from an R&D program, the R&D money is being wasted.
Congress should make a note that Research and Development, as conducted by US agencies in the US government should also be susceptible to critical analysis. Of the billions of dollars spent by these various agencies on R&D, what successes have we had for our money?. If we find insufficient success, we should be making major cuts, as has Sanofi.
The fact that Sanofi is a private company and can go out of business if it doesn't perform efficiently, while the US government cannot fail, is no excuse for continued government R&D inefficiency.
Congratulations to Sanofi in recognizing that R&D is a part of business success. If there is no progress with the development of new products from an R&D program, the R&D money is being wasted.
Congress should make a note that Research and Development, as conducted by US agencies in the US government should also be susceptible to critical analysis. Of the billions of dollars spent by these various agencies on R&D, what successes have we had for our money?. If we find insufficient success, we should be making major cuts, as has Sanofi.
The fact that Sanofi is a private company and can go out of business if it doesn't perform efficiently, while the US government cannot fail, is no excuse for continued government R&D inefficiency.
No comments:
Post a Comment